- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06037213
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
September 13, 2023 updated by: Peking Union Medical College Hospital
Non-interventional Study to Collect Real-world Patient-Reported Outcomes Data in Platinum-Sensitive Relapsed Ovarian Cancer Patients With Long-Term Use of Niraparib
This prospective, non-interventional study is designed to evaluate the quality of life of Chinese ovarian cancer patients with long-term niraparib use in a real-world setting.
Participants will complete questionnaires or accept telephone follow-up to provide information about their quality of life.
Study Overview
Status
Recruiting
Conditions
Detailed Description
In this prospective, non-interventional study, patients with platinum-sensitive relapsed ovarian cancer who have received niraparib as maintenance therapy for more than two years will agree to be contacted by questionnaire or telephone three times.
The interval will be 4-6 weeks.
Information on quality of life will be collected and analysed.
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Peng Peng, MD.
- Phone Number: +86-13521361934
- Email: pengp1999@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100032
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Peng Peng, MD.
- Phone Number: +86-13521361934
- Email: pengp1999@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients are members of the patient assistance programme population.
Description
Inclusion Criteria:
- Age ≥18 years
- Histologically confirmed platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
- Maintenance treatment with niraparib for ≥2 years and continuing for the next 28 days
- No significant cognitive impairment
- Understand the trial procedure and be able to sign the informed consent form before any study-related procedures
Exclusion Criteria:
- Patients who are not suitable for participation in this study according to the investigator's evaluation
- Patients receiving antineoplastic drugs for other malignancies
- Patients who are unable to comply with the protocol procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-reported health-related quality of life (HRQoL) - EQ-5D-5L questionnaire
Time Frame: 4 months
|
The EQ-5D is a standardized measure of health status applicable to a wide range of health conditions and treatments designed by the EuroQoL Group (EQ).
It consists of the EQ-5D-5L descriptive system, which comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with each dimension having 5 levels (5L), and the EQ visual analogue scale (EQ VAS)
|
4 months
|
|
Patient-reported health-related quality of life (HRQoL) - FOSI questionnaire
Time Frame: 4 months
|
The FOSI (Functional Assessment of Cancer Therapy-Ovarian Symptom Index) is a validated tool with eight items that measure response to treatment based on symptom assessment.
The questions assess pain, fatigue, nausea, vomiting, bloating, cramping, worry, and QoL.
Patients report their symptoms over the past week using a five-point Likert scale, which ranges from 0 (not at all) to 4 (very much).
|
4 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient population checklist
Time Frame: at baseline
|
Baseline characteristics, disease history, comorbidities and concomitant treatments, education.
|
at baseline
|
|
Niraparib medication checklist
Time Frame: at baseline
|
Starting dose, dose modification.
|
at baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yang Xiang, MD., Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 23, 2023
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
January 31, 2024
Study Registration Dates
First Submitted
September 8, 2023
First Submitted That Met QC Criteria
September 13, 2023
First Posted (Actual)
September 14, 2023
Study Record Updates
Last Update Posted (Actual)
September 14, 2023
Last Update Submitted That Met QC Criteria
September 13, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
Other Study ID Numbers
- PekingUMCH-PRO1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.